Life sciences news
-
Nathalie Draux succeeds Philippe Draux as CEO of Quality Assistance
Tuesday November 22nd 2022
Read more
-
argenx announces U.S. FDA acceptance of biologics license application for subcutaneous efgartigimod in generalized myasthenia gravis with priority review
Tuesday November 22nd 2022
Read more
-
Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023
Monday November 21st 2022
Read more
-
BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma
Thursday November 17th 2022
Read more
-
Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia
Tuesday November 15th 2022
Read more
-
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
Tuesday November 15th 2022
Read more
-
UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
Monday November 14th 2022
Read more
-
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Friday November 11th 2022
Read more
-
Become a flanders.bio member
Your news here?
-
Is Belgium becoming a hub for gene therapy?
Thursday November 10th 2022
Read more
-
The QbD Group acquires regulatory affairs and pharmacovigilance company EUDRAC Ltd to expand its services for pharmaceutical customers
Tuesday November 8th 2022
Read more
-
New Idylla™ EGFR study shows reduction of time-to-treatment by 48% for lung cancer patients
Tuesday November 8th 2022
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
